Advertisement


Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Welcome and Introduction to Vi3C

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Advertisement

Advertisement




Advertisement